Theriva Biologics, Inc. (TOVX) Stock Price, Quote & AI Analysis

Live TOVX stock price, real-time charts, AI-powered trade signals, technical analysis, earnings insights, and market sentiment for Theriva Biologics, Inc..

TradeVae provides AI-driven analysis and real-time market intelligence for Theriva Biologics, Inc. (TOVX), including price action, technical indicators, earnings performance, analyst sentiment, and short-term trade setups.

T
TOVX
Theriva Biologics, Inc.
real-time
$0.00 +0.00 (+0.00%)
Open
0.180000
High
0.185200
Low
0.180000
Volume
267,291
VWAP
-
Market Cap
$6,423,902.82
52W Range
$0.17 - $1.75
P/E Ratio
-
EPS
-
Debt/Equity
-
EV/EBITDA
-
Upcoming Earnings
Mar 4, 2026 Q4
After Hours
EPS Estimate: $-0.4437
Loading chart...

AI Analysis

Explore comprehensive AI-powered analysis including summary insights, bull and bear cases, key risks, and factors to watch.

Loading...

Generating AI analysis...

-
-
-
-

Theriva Biologics, Inc.'s fundamentals reflect its scale, profitability, and position within the global technology sector. Key valuation and financial metrics are summarized below, followed by detailed financial statements.

Theriva Biologics, Inc. Overview

Company information

Company Overview

Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-020 and SYN-004. SYN-020 is intended to prevent the antibiotic-mediated microbiome damage, C. difficile infections (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host disease (aGVHD) in allogeneic HCT recipients. SYN-004 is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer on January 8, 2001 and is headquartered in Rockville, MD.

Company Details
Market Cap
$6.52M
Shares Outstanding
35,688,400
Weighted Shares Outstanding
35,688,349
CEO
Steven A. Shallcross
Address
9605 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
Employees
22
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
XASE

Technical Indicators

Key technical analysis metrics and signals

Loading...

Loading technical indicators...

Valuation Metrics

Key valuation ratios and comparisons

Loading...

Loading valuation metrics...

Theriva Biologics, Inc. Earnings & Financial Statements

Earnings Calendar

Upcoming earnings dates and historical surprises

Loading...

Loading earnings calendar...

Financial Statements

Income statements, balance sheets, and cash flow

Loading...

Loading income statements...

Loading...

Loading balance sheets...

Loading...

Loading cash flow statements...